ReNerve inks Middle East distribution deal for nerve repair product NervAlign

ReNerve partners with Union MediScience B.S.C in exclusive distribution agreement for Middle East
Partnership covers sales and marketing of ReNerve’s primary product, the NervAlign Nerve Cuff
Middle East is a key international market target for ReNerve, with fewer competitors than US

Special Report: Nerve-repair company ReNerve has inked an exclusive distribution partnership in the Middle East with an established supplier – Bahrain-based Union MediScience B.S.C to further accelerate its international expansion.

Under the deal Union MediScience will sell and market ReNerve’s (ASX:RNV) primary product, the NervAlign nerve cuff, across five countries in the Middle East including Bahrain, Saudi Arabia, Kuwait, UAE/Dubai and Qatar.

The company’s trademarked NervAlign is a cuff to prevent scarring and inflammation when a nerve is being fixed and was approved by the US Food and Drug Administration (FDA) in 2022 and is commercially available in the US.

NervAlign has been specifically designed to protect a nerve for two to four months while it’s healing and then be naturally absorbed, so avoiding need for further surgery and potential risk of longer-term issues.

Established in 1988, Union MediScience is a medical distributor across the region representing global manufacturers with experience in tissue-based products.

ReNerve said the company has been a top supplier in the Bahrain market for more than two decades, earning a reputation for meeting customer requirements and delivering, installing and commissioning specified products on time.

Strategic expansion and targeted market entry

ReNerve is looking to capitalise on the growing global nerve-repair biomaterials market, which it noted is valued at US$1.96 billion in 2024 and projected to grow at a CAGR of 17.8% from 2024 to 2031, reaching US $6.19 bn.

The Middle East presents strong growth opportunities, the company emphasised, as awareness of the importance of nerve repair and replacement increases.

According to ReNerve, reports estimate the total Middle East and North Africa (MENA) market is worth over US$80m per annum and growing at over 35%.

ReNerve said the MENA region also has fewer competitors compared to larger markets such as the US.

The company added it remains well placed to accelerate its international expansion into the Middle East, along with regulatory programs in other jurisdictions, including Hong Kong.

‘Addressing significant unmet medical needs’

ReNerve managing director Dr Julian Chick said the distribution deal with Union MediScience underscores the company’s commitment to working with trusted local partners that possess deep regional expertise and established networks.

“This partnership aligns seamlessly with ReNerve’s strategic focus on global expansion and targeted market entry.

“By collaborating with Union MediScience, ReNerve leverages a partner with proven expertise and established connections, facilitating regulatory approvals and accelerating market penetration across the MENA region.

“Furthermore, the deal supported the company’s broader vision of commercialising cutting-edge medical technologies in high-growth markets while addressing significant unmet medical needs.”

This article was developed in collaboration with ReNerve, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.